Evaluating Treatment Resistant Dermatitis TaroIIR
Source: ClinicalTrials.gov NCT03050294 ↗No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Investigator Global Assessment- Atopic Dermatitis |
1.7; 1.5 | — |
| PRIMARY Investigator Global Assessment- Psoriasis |
2.5; 2.3 | — |
| SECONDARY Total Lesion Severity Score- Atopic Dermatitis |
3.8; 4.7 | — |
| SECONDARY Total Lesion Severity Score-Psoriasis |
6.5; 5.8 | — |
| SECONDARY Eczema Area and Severity Index- Atopic Dermatitis |
3.1; 1.2 | — |
| SECONDARY Pruritus Visual Analog Scale- Atopic Dermatitis |
1.1; 1.2 | — |
| SECONDARY Pruritus Visual Analog Scale- Psoriasis |
1.4; 1.3 | — |
| SECONDARY Psoriasis Area and Severity Index |
7.1; 5.1 | — |
Eligibility Criteria
Inclusion Criteria
Male or female ≥18 years of age at baseline visit.
Documentation of plaque-type psoriasis or atopic dermatitis diagnosis as evidenced by one or more clinical features
Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
Exclusion Criteria
Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
No access to a phone throughout the day
Subject is diagnosed with a disease that is known to effect adherence and would otherwise bias our results (Such as Alzheimer's or dementia)
Patient had a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance that, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
Data sourced from ClinicalTrials.gov (NCT03050294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.